JCR Pharmaceuticals Co. Ltd.

10/18/2021 | Press release | Distributed by Public on 10/18/2021 01:00

EMA grants PRIME Designation for JR-141 for the treatment of Mucopolysaccharidosis Type II (Hunter Syndrome)